Loading...
Amylyx Pharmaceuticals, Inc.
AMLX•NASDAQ
Healthcare
Biotechnology
$7.63
$0.38(5.32%)
Amylyx Pharmaceuticals, Inc. (AMLX) Financial Performance & Statements
Review Amylyx Pharmaceuticals, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
-77.06%
↓ 77.06%
Operating Income Growth
-911.12%
↓ 911.12%
Net Income Growth
-712.42%
↓ 712.42%
Operating Cash Flow Growth
-1506.55%
↓ 1506.55%
Operating Margin
16317.06%
↑ 16317.06%
Gross Margin
775.71%
↑ 775.71%
Net Profit Margin
17205.74%
↑ 17205.74%
ROE
-106.28%
↓ 106.28%
ROIC
-102.88%
↓ 102.88%
Amylyx Pharmaceuticals, Inc. (AMLX) Financial Statements
Explore quarterly and annual reports for Amylyx Pharmaceuticals, Inc. stock.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | -$665000.00 | $416000.00 | -$1.02M | $88.64M |
| Cost of Revenue | $160000.00 | $809000.00 | $7.63M | $116.72M |
| Gross Profit | -$825000.00 | -$393000.00 | -$8.65M | -$28.08M |
| Gross Profit Ratio | $1.24 | -$0.94 | $8.45 | -$0.32 |
| R&D Expenses | $22.73M | $21.24M | $23.14M | $36.29M |
| SG&A Expenses | $17.10M | $17.83M | $21.65M | $57.76M |
| Operating Expenses | $39.99M | $75.27M | $44.79M | $94.05M |
| Total Costs & Expenses | $39.99M | $76.08M | $52.41M | $210.77M |
| Interest Income | $2.32M | $3.10M | $4.07M | $4.33M |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $160000.00 | $221000.00 | $208000.00 | $315000.00 |
| EBITDA | -$40.49M | -$39.24M | -$53.23M | -$121.81M |
| EBITDA Ratio | $60.89 | -$94.32 | $52.03 | -$1.37 |
| Operating Income | -$40.65M | -$75.66M | -$53.44M | -$122.13M |
| Operating Income Ratio | $61.13 | -$181.88 | $52.23 | -$1.38 |
| Other Income/Expenses (Net) | $2.47M | $2.96M | -$19.27M | $3.58M |
| Income Before Tax | -$38.18M | -$72.70M | -$72.70M | -$118.55M |
| Income Before Tax Ratio | $57.42 | -$174.77 | $71.07 | -$1.34 |
| Income Tax Expense | -$635000.00 | $0.00 | $0.00 | $242000.00 |
| Net Income | -$37.55M | -$72.70M | -$72.70M | -$118.79M |
| Net Income Ratio | $56.46 | -$174.77 | $71.07 | -$1.34 |
| EPS | -$0.55 | -$1.07 | -$1.07 | -$1.75 |
| Diluted EPS | -$0.55 | -$1.07 | -$1.07 | -$1.75 |
| Weighted Avg Shares Outstanding | $68.59M | $68.09M | $68.02M | $67.85M |
| Weighted Avg Shares Outstanding (Diluted) | $68.59M | $68.09M | $68.02M | $67.85M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan